Industry News
Pharmaceutical Industry News
Since investment bank HSBC…
Since investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of the Indianapolis drugmaker has dropped by more than 7%. Creating the stir was a
According to a review by The New…
According to a review by The New York Times, the MFN prices offered on certain drugs through the government's TrumpRx platform may still be higher than those of other countries.
The once-daily pill stands to…
The once-daily pill stands to shake up the injectable-filled psoriasis market and is in line for blockbuster-level sales.
Bristol Myers Squibb has added a…
Bristol Myers Squibb has added a familiar face to an ongoing initiative to thank oncologists for the valuable time they return to cancer patients’ lives.
Sandoz has struck a deal with…
Sandoz has struck a deal with Samsung Bioepis to commercialize up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio, which is being developed by the South Korea-based biosimilars specialist.
Bill Gates-founded TerraPower…
Bill Gates-founded TerraPower Isotopes—which produces actinium-225 derived from legacy U.S. nuclear material—is laying out nearly half a billion dollars as it seeks to become the “premier global distributor” of the rare and promising ingredient.
The next generation of MLR…
The next generation of MLR platforms will not be defined solely by automation or AI—but by their ability to adapt to the organizations using them. ERMA Evaluate™ is helping life sciences teams move beyond rigid
How TrumpRx Drug Prices Compare With Those in Other Countries
The TrumpRx website claims to offer the best prices for medications. Here’s where Americans still pay more — and much more.
It’s Cruel to Take Away People’s H.I.V. Medication
States are rolling back coverage for lifesaving medications.
Indiana’s governor Mike Braun aims…
Indiana's governor Mike Braun aims to create 100,000 "high wage" jobs over the next decade through the plan, with hopes of transforming the state into the "premier destination" for life sciences innovation.
More than 20 years after gaining…
More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, according to a report released by
It’s time once again for Fierce…
It’s time once again for Fierce Pharma Marketing’s annual #FierceMadness tournament. This time around, we're watching 64 newly minted drug names go head to head.
In its fifth year, the annual…
In its fifth year, the annual Hologic Global Women’s Health Index found only minimal improvements in preventive screening rates from the first report, and no change at all in an overall analysis of women’s health
Amid the U.S.’ war with Iran,…
Amid the U.S.' war with Iran, generic exports, drugs for clinical trials and local shipments of biologics that rely on cold chains in the region are likely to face increasing pressure if the conflict persists,
The company evaluated MC4R agonist…
The company evaluated MC4R agonist Imcivree across four genetic-driven obesity subgroups, with the treatment missing the primary BMI endpoint in each substudy.
Moderna CEO Stéphane Bancel’s…
Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable in 2025 despite the company’s revenue miss. Following a major cost-cutting initiative, the CEO’s pay package was bolstered by a $4.3 million cash bonus, the highest
A federal judge in Boston blocked…
A federal judge in Boston blocked significant parts of the HHS' vaccination agenda and effectively stopped an upcoming vaccines advisory panel from meeting later this week as originally scheduled.
While BioMarin has been focusing…
While BioMarin has been focusing heavily on its CNP analogue, Voxzogo, to write the next chapter of the company’s growth story, a change in its clinical development plans introduces further uncertainty into the company’s calculus.
Amgen’s Amjevita, Aimovig and…
Amgen’s Amjevita, Aimovig and Repatha—plus GSK's Ellipta inhalers and its Relenza—became available through the government drug platform on Monday.
Idorsia is gearing up for another…
Idorsia is gearing up for another CEO change with the news that Srishti Gupta, M.D., is leaving the company. As the company commences its search for a new CEO, board chair Jean-Paul Clozel, M.D., is